Clinical Trials
43
1 active
Approvals
3
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
Completed
39
90.7%
Not yet recruiting
1
2.3%
Recruiting
1
2.3%
Terminated
2
4.7%
- Obesity medication prescriptions among US adolescents aged 12-17 years increased by 301.7% between 2020 and 2023, driven primarily by FDA approvals of semaglutide and phentermine-topiramate for pediatric use. - Despite the dramatic increase, only 0.5% of adolescents with obesity received medication prescriptions in 2023, highlighting significant treatment gaps in this population. - Substantial disparities emerged in prescribing patterns, with Black adolescents receiving medications at lower rates than White adolescents despite having higher rates of severe obesity. - Access barriers including high out-of-pocket costs, insurance coverage limitations, and provider knowledge gaps continue to limit widespread adoption of evidence-based obesity treatments.
- VIVUS LLC has launched QSYMIA (phentermine and topiramate extended-release) in the United Arab Emirates for treating obesity in adults and children aged 12 and older, marking the first Middle Eastern country to approve the medication. - The World Obesity Federation projects that by 2035, approximately 7.5 million UAE residents will be overweight or living with obesity, with current obesity-related costs reaching nearly $12 billion annually. - VIVUS aims to expand QSYMIA's global reach to over one billion individuals by the end of 2025, with the medication already approved in several European countries under the brand name QSIVA.
